+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis

Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis

Digestive & Liver Disease 34(7): 523-527

Background. Ursodeoxycholic acid is currently used for the treatment of primary biliary cirrhosis at 13-15 mg/kg/day, but liver tests of some patients do not return to normal at this dose. Studies reported here were designed to test whether a higher dose of ursodeoxycholic acid than is currently used would induce still greater biliary enrichment of ursodeoxycholic acid and whether such enrichment would lead to still further improvement in liver tests in patients with early primary biliary cirrhosis. Methods. A total of 20 patients with histologically proven primary biliary cirrhosis were enrolled. Patients had early stage primary biliary cirrhosis as serum bilirubin levels were normal and the Mayo risk score 4.2+-0.5. Group 1 received 600, 1200 and 1800 mg/day of ursodeoxycholic acid; group 2 received 900, 1500 and 2100 mg/day. The order of periods was randomized. Each treatment period lasted 3 months followed by a further 3 months during which a standard dose of ursodeoxycholic acid was given. At the end of each treatment period, liver tests were evaluated, and biliary bile acid pattern of duodenal bile was determined using high pressure liquid chromatography. Results. Biliary bile acid became enriched in ursodeoxycholic acid in direct relationship to dosage (r=0.84, p<0.001). At doses of 1800 mg/day (25-35 mg/kg/day), biliary ursodeoxycholic acid averaged 69+-6.6%. A progressive decrease of alanine aminotransferase (p<0.0001), aspartate aminotransferase (p<0.001) and alkaline phosphatase (p<0.02) was observed with increasing concentrations of ursodeoxycholic acid in bile. Biochemical liver tests showed a stronger correlation with biliary concentrations of ursodeoxycholic acid than with the administered dose. Conclusions. In early primary biliary cirrhosis, higher dose ursodeoxycholic acid appears to be more effective than doses currently recommended.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 010807617

Download citation: RISBibTeXText

PMID: 12236487

DOI: 10.1016/s1590-8658(02)80112-8

Related references

Greater biliary enrichment and improved liver tests with higher doses of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 120(5 Supplement 1): A 574, 2001

Effects of ursodeoxycholic acid udca on liver function tests and bile acid metabolism in anicteric primary biliary cirrhosis pbc a dose response study. Hepatology 8(5): 1266, 1988

Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis. Journal of the Formosan Medical Association 90(10): 970-974, 1991

Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 40(3): 693-698, 2004

Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis. Hepatology Research 44(9): 993-999, 2013

Ursodeoxycholic acid therapy from primary biliary cirrhosis progression of disease despite near normalization of biochemical liver tests. Hepatology 12(4 PART 2): 843, 1990

Markedly decreased biliary ursodeoxycholic acid enrichment with high dose UDCA in cystic fibrosis associated liver disease Optimization of the therapeutic dose. Hepatology 20(4 PART 2): 262A, 1994

Effect of long term ursodeoxycholic acid treatment on quantitative liver function tests in primary biliary cirrhosis. European Journal of Clinical Investigation 21(2 PART 2): 52, 1991

Response to IV pulsed high dose corticosteroid therapy of primary biliary cirrhosis resistant to ursodeoxycholic acid. Journal of Hepatology 26(SUPPL 1): 302, 1997

Primary biliary cirrhosis Standard liver function tests during long term treatment with ursodeoxycholic acid and value of serial quantitative liver function tests. Gastroenterology 112(4 SUPPL ): A1377, 1997

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. Journal of Hepatology 25(1): 49-57, 1996

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology 11(10): 1069-1076, 1999

Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 29(6): 1649-1654, 1999

Ursodeoxycholic acid in primary biliary cirrhosis - A cochrane hepato-biliary systematic review. Journal of Hepatology 30(SUPPL 1): 83, 1999

Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. American Journal of Gastroenterology 86(9): 1194-1199, 1991